UK markets close in 45 minutes

Biotest Aktiengesellschaft (0N6Z.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
43.00+0.10 (+0.23%)
As of 05:21PM BST. Market open.
Full screen
Previous close42.90
Open43.00
Bid0.00 x N/A
Ask0.00 x N/A
Day's range43.00 - 43.00
52-week range43.00 - 43.00
Volume118
Avg. volumeN/A
Market cap15.485M
Beta (5Y monthly)0.43
PE ratio (TTM)N/A
EPS (TTM)-1.37
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Biotest AG: Biotest AG opens 13th plasma collection centre in the Czech Republic

    EQS-News: Biotest AG / Key word(s): MiscellaneousBiotest AG: Biotest AG opens 13th plasma collection centre in the Czech Republic 26.09.2022 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. PRESS RELEASE Biotest AG opens 13th plasma collection centre in the Czech Republic 33 plasma collection stations in Europe to secure the plasma supply in the long termDreieich, 26 September 2022. Biotest has received the operating licence for the 13th Cara Plasma plasmaph

  • EQS Group

    Biotest AG: Biotest AG opens 12th plasma collection centre in the Czech Republic

    DGAP-News: Biotest AG / Key word(s): MiscellaneousBiotest AG: Biotest AG opens 12th plasma collection centre in the Czech Republic 06.09.2022 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. PRESS RELEASE Biotest AG opens 12th plasma collection centre in the Czech Republic 32 plasma collection stations in Europe to secure the plasma supply in the long termDreieich, 06 September 2022. Biotest has received the operating licence for the 12th Cara Plasma plasmap

  • EQS Group

    Biotest AG: Biotest achieves an improved adjusted EBIT by 9.8% of EUR 32.4 million in the first half of 2022

    DGAP-News: Biotest AG / Key word(s): Half Year ResultsBiotest AG: Biotest achieves an improved adjusted EBIT by 9.8% of EUR 32.4 million in the first half of 2022 11.08.2022 / 07:00 The issuer is solely responsible for the content of this announcement. PRESS RELEASE Biotest achieves an improved adjusted EBIT by 9.8% of € 32.4 million in the first half of 2022 Biotest almost reaches previous year's turnover of € 253 million in a difficult environment Opening of four plasma collection centres in t